|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Upon stimulation with peptides, GAD-specific responses were equally broad in subjects with diabetes and healthy controls in the presence or absence of CD25(+) T cells, suggesting that a susceptible HLA is sufficient to generate a potentially autoreactive repertoire.
|
23228173 |
2013 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Our results indicate that a single subcutaneous hindpaw inoculation of vectors expressing GAD65 or GAD67 reduced diabetes-induced mechanical allodynia to a degree that was greater than daily injections of gabapentin in rats.
|
23235561 |
2013 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The ages of development of insulin autoantibodies (IAA) and GAD autoantibodies (GADA), followed by multiple islet autoantibodies and progression to diabetes were examined in 2,441 children participating in two German birth cohorts.
|
26138334 |
2015 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Autoantibodies to GAD65(96-585) in relatives are more closely associated with diabetes risk than those to full-length GAD, suggesting that assays using N-terminally truncated GAD should be used to select participants for intervention trials.
|
26001397 |
2015 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Here, we examined whether an unbiased stratification of diabetes according to age at onset, fasting C-peptide and GAD autoantibodies (GADab) defines groups with differences in glycaemic control and markers of cardiometabolic risk.
|
28987750 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Activation of CD4+ and CD8+ T-lymphocytes by insulin and GAD in patients with type 1 or 2 diabetes mellitus.
|
28986401 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
They focused testing on patients negative for both GAD and islet antigen 2 (IA-2) islet autoantibodies, thereby ruling out those with markers of type 1 diabetes, the most common form of diabetes in this age group.
|
28132100 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Relatives found to be GAD antibody-positive using these truncated labels were at increased risk of diabetes progression within 15 years, compared with those positive for GAD(1-585) antibody only, and at similar risk to those found GAD antibody-positive by ELISA.
|
29577424 |
2018 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
KPD is defined as a syndrome in which diabetes commences with ketoacidosis in individuals who are GAD and anti-islet cell antibody negative and have no known precipitating causes.
|
30280274 |
2018 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
However, those with later onset type 1 diabetes had a modestly lower type 1 diabetes genetic risk score (0.268 vs 0.279; p < 0.001 [expected type 2 diabetes population median, 0.231]), a higher islet autoantibody prevalence (GAD-, islet antigen 2 [IA2]- or zinc transporter protein 8 [ZnT8]-positive) of 78% at 13 years vs 62% at 26 years of diabetes duration; (p = 0.02), and were less likely to identify as having type 1 diabetes (79% vs 100%; p < 0.001) vs those with young-onset disease.
|
30969375 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
We investigated associations of antibodies against the 65 kDa isoform of GAD (GAD65) with type 1 diabetes and type 2 diabetes genetic risk scores and incident diabetes in adults in European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct, a case-cohort study nested in the EPIC cohort.
|
31713011 |
2020 |